Summary by Futu AI
Wuxi Bio announced its business performance for the first half of 2024, with a slight increase in revenue of 1.0% to RMB 857.42 million, a decrease in gross margin of 2.8 percentage points to 39.1%, and a significant decline in net profit of 23.9% to RMB 178.03 million. The company's attributable net profit also decreased by 33.9% to RMB 149.91 million. Despite facing challenges, Wuxi Bio maintained steady business development with a significant increase in the number of projects, bringing the total number of projects to 742. The board of directors has decided not to distribute interim dividends. Looking ahead, Wuxi Bio will continue to invest in enhancing capabilities and scale to support sustainable growth.